JP2012509071A5 - - Google Patents

Download PDF

Info

Publication number
JP2012509071A5
JP2012509071A5 JP2011536741A JP2011536741A JP2012509071A5 JP 2012509071 A5 JP2012509071 A5 JP 2012509071A5 JP 2011536741 A JP2011536741 A JP 2011536741A JP 2011536741 A JP2011536741 A JP 2011536741A JP 2012509071 A5 JP2012509071 A5 JP 2012509071A5
Authority
JP
Japan
Prior art keywords
nucleic acid
acid construct
invariant chain
protein
peptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2011536741A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012509071A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/DK2009/050310 external-priority patent/WO2010057501A1/en
Publication of JP2012509071A publication Critical patent/JP2012509071A/ja
Publication of JP2012509071A5 publication Critical patent/JP2012509071A5/ja
Pending legal-status Critical Current

Links

JP2011536741A 2008-11-21 2009-11-20 免疫応答のプライミング Pending JP2012509071A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA200801638 2008-11-21
DKPA200801638 2008-11-21
PCT/DK2009/050310 WO2010057501A1 (en) 2008-11-21 2009-11-20 Priming of an immune response

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2014226711A Division JP2015061530A (ja) 2008-11-21 2014-11-07 免疫応答のプライミング

Publications (2)

Publication Number Publication Date
JP2012509071A JP2012509071A (ja) 2012-04-19
JP2012509071A5 true JP2012509071A5 (enExample) 2013-01-24

Family

ID=40823418

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2011536741A Pending JP2012509071A (ja) 2008-11-21 2009-11-20 免疫応答のプライミング
JP2014226711A Pending JP2015061530A (ja) 2008-11-21 2014-11-07 免疫応答のプライミング
JP2017011749A Pending JP2017131220A (ja) 2008-11-21 2017-01-26 免疫応答のプライミング
JP2019091809A Active JP6825036B2 (ja) 2008-11-21 2019-05-15 免疫応答のプライミング

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2014226711A Pending JP2015061530A (ja) 2008-11-21 2014-11-07 免疫応答のプライミング
JP2017011749A Pending JP2017131220A (ja) 2008-11-21 2017-01-26 免疫応答のプライミング
JP2019091809A Active JP6825036B2 (ja) 2008-11-21 2019-05-15 免疫応答のプライミング

Country Status (20)

Country Link
US (4) US20110293704A1 (enExample)
EP (3) EP3552622A3 (enExample)
JP (4) JP2012509071A (enExample)
CN (3) CN102292102A (enExample)
AU (1) AU2009317691A1 (enExample)
BR (1) BRPI0921927B8 (enExample)
CA (1) CA2743229A1 (enExample)
CY (1) CY1122117T1 (enExample)
DK (1) DK2865387T3 (enExample)
ES (1) ES2743677T3 (enExample)
HK (1) HK1209645A1 (enExample)
HR (1) HRP20191594T1 (enExample)
HU (1) HUE045093T2 (enExample)
IL (4) IL212914A0 (enExample)
LT (1) LT2865387T (enExample)
PL (1) PL2865387T3 (enExample)
PT (1) PT2865387T (enExample)
RU (2) RU2011125306A (enExample)
SI (1) SI2865387T1 (enExample)
WO (1) WO2010057501A1 (enExample)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ616957A (en) 2007-02-19 2015-06-26 Marinepolymer Tech Inc Hemostatic compositions and therapeutic regimens
BR112012030794B1 (pt) * 2010-06-04 2019-11-26 Inserm ( Institut National De La Santé Et De La Recherche Médicale) Novos compostos imunoadjuvantes e usos dos mesmos
GB201115095D0 (en) 2011-09-01 2011-10-19 Singapore Volition Pte Ltd Method for detecting nucleosomes containing nucleotides
US20140348863A1 (en) * 2011-10-12 2014-11-27 Alessia Bianchi Cmv antigens and uses thereof
KR102039756B1 (ko) 2011-12-07 2019-11-01 벨지언 볼리션 에스피알엘 뉴클레오솜 부가물의 검출 방법
EP2877205A4 (en) * 2012-07-26 2016-04-06 Jackson H M Found Military Med VACCINE WITH A MULTIMED FUSION PROTEIN AND IMMUNOTHERAPY
MX368258B (es) 2013-03-15 2019-09-25 Zymeworks Inc Compuestos citotoxicos y antimitoticos y metodos de uso de los mismos.
US10576143B2 (en) 2013-03-15 2020-03-03 Glaxosmithkline Biologicals Sa Poxviral vaccines
WO2014139587A1 (en) 2013-03-15 2014-09-18 Okairòs Ag Improved poxviral vaccines
AU2014310933B2 (en) * 2013-08-21 2020-05-14 CureVac SE Method for increasing expression of RNA-encoded proteins
GB201321384D0 (en) * 2013-12-04 2014-01-15 Isis Innovation Molecular adjuvant
BR112016015105A8 (pt) * 2013-12-27 2018-04-24 Var2 Pharmaceuticals Aps conjugados var2csa-droga
KR102384740B1 (ko) 2013-12-27 2022-04-07 자임워크스 인코포레이티드 약물 접합체를 위한 설폰아마이드-함유 연결 시스템
AU2015318556C1 (en) 2014-09-17 2021-01-07 Zymeworks Bc Inc. Cytotoxic and anti-mitotic compounds, and methods of using the same
WO2017025782A1 (en) 2014-09-17 2017-02-16 Glaxosmithkline Biologicals Sa Improved poxviral vaccines
AU2016339924B2 (en) * 2015-10-12 2020-01-02 Nantomics, Llc Compositions and methods for viral cancer neoepitopes
EP4299136A3 (en) 2015-12-16 2024-02-14 Gritstone bio, Inc. Neoantigen identification, manufacture, and use
WO2018037045A1 (en) 2016-08-23 2018-03-01 Glaxosmithkline Biologicals Sa Fusion peptides with antigens linked to short fragments of invariant chain (cd74)
BE1024774B1 (fr) 2016-09-29 2018-07-02 Glaxosmithkline Biologicals Sa Compositions et procedes de traitement
US10517958B2 (en) 2016-10-04 2019-12-31 Zymeworks Inc. Compositions and methods for the treatment of platinum-drug resistant cancer
GB201620968D0 (en) 2016-12-09 2017-01-25 Glaxosmithkline Biologicals Sa Adenovirus polynucleotides and polypeptides
GB201704417D0 (en) 2017-03-20 2017-05-03 Univ Copenhagen Improved li vaccine adjuvant
AU2018300051B2 (en) * 2017-07-12 2024-12-19 Nouscom Ag Neoantigen vaccine composition for treatment of cancer
EP3694532B1 (en) 2017-10-10 2025-02-26 Gritstone bio, Inc. Neoantigen identification using hotspots
BR112020008308A2 (pt) * 2017-11-03 2020-11-17 Nouscom Ag polipeptídeo, polinucleotídeo, vetor, coleção de dois ou mais vetores, composição farmacêutica e kit
IL274799B2 (en) 2017-11-22 2025-05-01 Gritstone Bio Inc Reducing junction epitope presentation for neoantigens
GB201721069D0 (en) 2017-12-15 2018-01-31 Glaxosmithkline Biologicals Sa Hepatitis B Immunisation regimen and compositions
GB201721068D0 (en) 2017-12-15 2018-01-31 Glaxosmithkline Biologicals Sa Hepatitis B immunisation regimen and compositions
CN108285885A (zh) * 2017-12-28 2018-07-17 中国农业大学 一种霍乱弧菌菌影制备方法及其在家禽疫苗中的应用
CA3102224A1 (en) 2018-06-12 2019-12-19 Glaxosmithkline Biologicals Sa Chimpanzee adenovirus chad157 polynucleotides, polypeptides.vectors, compositions, cells and uses thereof
MX2021004425A (es) * 2018-10-19 2021-07-06 Nouscom Ag Vacuna contra cancer de cadena invariante de teleosteo.
WO2020128012A1 (en) 2018-12-21 2020-06-25 Glaxosmithkline Biologicals Sa Methods of inducing an immune response
RU2725493C2 (ru) * 2018-12-28 2020-07-02 Федеральное государственное бюджетное учреждение науки институт биоорганической химии им. академиков М.М. Шемякина и Ю.А. Овчинникова Российской академии наук (ИБХ РАН) Система для стабильной экспрессии опухоль-ассоциированных антигенов на основе лентивирусного вектора
EP3934687A1 (en) 2019-03-05 2022-01-12 GlaxoSmithKline Biologicals S.A. Hepatitis b immunisation regimen and compositions
CN111729093B (zh) * 2020-06-29 2022-05-24 南京超维景生物科技有限公司 一种造影剂成膜剂组合物、造影剂成膜脂液、造影剂及其制备方法
EP4137153A1 (en) 2021-08-18 2023-02-22 Sirion Biotech GmbH Therapeutic papilloma virus vaccines
CN120456919A (zh) 2022-12-19 2025-08-08 葛兰素史克生物有限公司 乙型肝炎组合物

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US587673A (en) 1897-08-03 higgins
US58767A (en) 1866-10-16 John brougjbton
US5554372A (en) 1986-09-22 1996-09-10 Emory University Methods and vaccines comprising surface-active copolymers
JP2682061B2 (ja) 1988-10-07 1997-11-26 藤沢薬品工業株式会社 ペプチドの分子内ジスルフィド結合の形成法
US5559028A (en) * 1993-05-19 1996-09-24 Antigen Express, Inc. Methods of enhancing or antigen presentation to T cells inhibiting
US5876735A (en) 1994-04-22 1999-03-02 Corixa Corporation Methods for enhancement of protective immune responses
WO1997010335A1 (de) * 1995-09-14 1997-03-20 Universität Tübingen Rekombinantes polypeptid basierend auf der primärsequenz der invarianten kette mit mindestens einer primärsequenz von einem spezifischen t-zellepitop oder eines proteinderivats und dieses rekombinante polypeptid kodierende nukleinsäuren
AU3307497A (en) * 1996-06-26 1998-01-14 Antigen Express, Inc. Immunotherapy by modulation of antigen presentation
ATE518956T1 (de) * 1998-05-13 2011-08-15 Epimmune Inc Expressionsvektoren zur stimulierung einer immunantwort und verfahren zu deren verwendung
US20030235594A1 (en) * 1999-09-14 2003-12-25 Antigen Express, Inc. Ii-Key/antigenic epitope hybrid peptide vaccines
US6432409B1 (en) * 1999-09-14 2002-08-13 Antigen Express, Inc. Hybrid peptides modulate the immune response
GB0208817D0 (en) 2002-04-17 2002-05-29 European Molecular Biology Lab Embl Method for producing monoclonal antibodies
US7179645B2 (en) * 2002-09-24 2007-02-20 Antigen Express, Inc. Ii-Key/antigenic epitope hybrid peptide vaccines
US20100278904A1 (en) * 2005-11-30 2010-11-04 Copenhagen University Nucleotide vaccine
US20080095798A1 (en) * 2006-10-18 2008-04-24 Robert Humphreys Ii-key enhanced vaccine potency
US9085638B2 (en) * 2007-03-07 2015-07-21 The Johns Hopkins University DNA vaccine enhancement with MHC class II activators
WO2010027973A1 (en) * 2008-09-02 2010-03-11 Antigen Express, Inc. Human papillomavirus / li-key hybrids and methods of use

Similar Documents

Publication Publication Date Title
JP2012509071A5 (enExample)
RU2011125306A (ru) Праймирование иммунного ответа
JP6321261B2 (ja) ワクチン組成物及びその使用方法
An et al. Silica nanoparticle as a lymph node targeting platform for vaccine delivery
RU2712743C2 (ru) Вакцина против бешенства
Andrianov et al. Molecular-level interactions of polyphosphazene immunoadjuvants and their potential role in antigen presentation and cell stimulation
Li et al. Rational design of T-cell-and B-cell-based therapeutic cancer vaccines
CA3036742A1 (en) Modified vsv-g and vaccines thereof
AU2016379413A1 (en) Covalent polymer-antigen conjugated particles
Wang et al. Cell penetrating peptide-based redox-sensitive vaccine delivery system for subcutaneous vaccination
JP2013532971A5 (enExample)
US20040033585A1 (en) Flexible vaccine assembly and vaccine delivery platform
Bolhassani et al. DNA immunization as an efficient strategy for vaccination
Jiang Cell-penetrating peptide-mediated nanovaccine delivery
WO2022043449A1 (en) Vaccines based on an antigen protein fused to a nanostructuring scaffold
Wang et al. Advances of nanotechnology toward vaccine development against animal infectious diseases
Ito et al. Antigen/adjuvant-displaying enveloped viral replica as a self-adjuvanting anti-breast-cancer vaccine candidate
KR20130044204A (ko) 점막 백신
JP5458286B1 (ja) 樹状細胞表面タンパク質に対する抗体を有するバイオナノカプセル
JP5901084B2 (ja) ペプチドアジュバント
Jin et al. Administration of soft matter lipid-DNA nanoparticle as the immunostimulant via multiple routes of injection in vivo
Bae et al. Potential of translationally controlled tumor protein-derived protein transduction domains as antigen carriers for nasal vaccine delivery
WO2005091753A2 (en) Flexible vaccine assembly and vaccine delivery platform
US20050282263A1 (en) Flexible vaccine assembly and vaccine delivery platform
Bolhassani et al. Non-viral delivery systems in gene therapy and vaccine development